Compare Abeona Therapeutics Inc (ABEO) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Intel Corp — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Intel Corp trades at $107.1 (market cap $554.82B). The key difference: Intel Corp is far larger — about 1486.2× Abeona Therapeutics Inc's market cap, and Intel Corp pays a 2.24% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | INTC | |
|---|---|---|
Market Cap | $373.32M | $554.82B |
Sector | Health | Technology |
52-Week High | $7.23 | $140.94 |
52-Week Low | $4.17 | $19.31 |
Enterprise Value | $228.22M | $567.06B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Intel (INTC) trades at $110.39, down 8.28% amid a sector-wide chip selloff triggered by Samsung's earnings reaction. Despite beating EPS estimates for three consecutive quarters, the stock shows weak profitability with a negative net income margin and ROE. Technical indicators are neutral, with support at $114 and resistance at $124. Cash flow improved in 2025, but revenue remains flat year-over-year, highlighting growth challenges.
The outlook is mixed: analyst consensus is a 'Hold' with a $97.74 price target below current levels, reflecting skepticism about near-term execution. Risks include intense competition and cyclical semiconductor demand, but potential upside exists if foundry partnerships and AI-driven CPU demand materialize as projected by bullish analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
